This trial involved 290 adults (149 males and 141 females), all of whom had ALK-positive non-small-cell lung cancer who had not been treated with an ALK-targeted medicine.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...

The FDA granted an accelerated approval for sunvozertinib (Zegfrovy; Dizal) on June 2, 2025, marking the first and only targeted oral treatment for patients with non–small cell lung cancer ...

Reply to: Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care The following represents disclosure ...

July 7, 2025 – The FDA has granted quick approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as ...

Lu S, Zhang W, Wu L, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA 2024;331:201-11.